To include your compound in the COVID-19 Resource Center, submit it here.

Buying local

How CanSino's $65M round could help its first three vaccines reach China market

CanSino Biologics Inc.’s investors are hoping a $65 million venture round will be enough to help the company launch a trio of products by 2019 to tap China’s growing demand for vaccines.

Future Industry Investment Fund, which is managed by the SDIC

Read the full 414 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE